X4制药 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the transition period from __________ to __________Commission File Number: 001-38295_____________________________________________________________________________________ X4 PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)_____________________________________________________________________________________ (857) 529-8300(Registrant’s telephone number, including area code)____________________________________________________________________________ Name of each exchange on which registered The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past90days.Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerginggrowth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of theExchange Act. Large accelerated filer☐Non-accelerated filer☒ Accelerated filer☐Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisedfinancial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May1, 2026, the registrant had 94,319,696 shares of common stock, $0.001 par value per share, outstanding. X4 PHARMACEUTICALS INC.TABLE OF CONTENTS CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In this Quarterly Report on Form 10-Q, unless context otherwise requires or where otherwise indicated, the terms “X4” “we,”“us,” “our,” and the “Company,” refer to X4 Pharmaceuticals, Inc. and its subsidiaries. This Quarterly Report on Form 10-Q containsforward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended (the “Securities Act”), andSection21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements ofhistorical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our plans, objectives, goals,strategies, future events, future operations, future financial position, future revenues or performance, projected costs, prospects,expectations, plans or intentions relating to clinical development, product candidates, the regulatory approval process, products andmarkets, and business trends and other information referred to in the sections titled “Risk Factors” and “Management’s Discussion andAnalysis of Financial Condition and Results of Operations,” are forward-looking statements. In some cases, these statements may beidentified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,”“estimates,” “predicts,” “potential,” “continue” or the negative of these terms or other comparable terminology. Our forward-lookingstatements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees offuture results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions, orexpectations disclosed in these forward-looking statements and actual results or events could differ materially from the plans,intentions and expectations disclosed in these forward-looking statements. These forward-looking statements are subject to a numberof known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” andelsewhere in this report, regarding, among other things: •our ability to raise additional capital or achieve sufficient revenue to properly fund our business and operatingplan as well as our ability to continue as a going concern;•our expectations and goals for commercialization of XOLREMDI(mavorixafor), which has been approved foruse as an oral, once-daily therapy to increase the number of circulating mature neutrophils and lymphocytes inpatients 12 years of age and older with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis)syndrome in the U.S., and that XOLREMDI, our one product approved for commercial sale, upon which wedepend almost entirely to produce revenue, faces an unknown market size and growth potentia